WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
No. 1 seed Texas, threePitcher Brayan Bello comes off IL to start against Nats; Josh Winckowski sent to TripleAustralia: Plane lands without landing gear after burning off fuelDoug Barron claims first PGA Tour Champions major with bogeyDanish butter tycoon's big coin collection could fetch up to $72 millionBruins captain Marchand scratched from Game 4 of Eastern Conference semifinals against PanthersU.S. gov't says weapons supplied to Israel may have been used in violation of int'l lawSundance Wicks returns to Wyoming as basketball coach after a year at Green BayChris Gotterup wins Myrtle Beach Classic for 1st PGA Tour titleHow Zendaya and Sydney Sweeney are taking Hollywood by storm with VERY different approaches
2.8459s , 6497.9453125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Stellar Storyline news portal